founder and CEO, Atlantis Consulting Group
Managing director, the Foundry Group
Executive Director, NY Tech Meetup and Advisor, Flybridge Capital
Professor of Leadership, Emeritus at the Harvard Business School
Co-Founder and CEO, Cascadia Capital
Professor of Computer Science, UC Berkeley
Founding Dir. Calit2
President and CEO, VLST Corporation
|
|
ProteoTech, a Kirkland, WA-based developer of neurology drugs, said it has raised $519,000 in a debt offering, according to a regulatory filing. The company, founded in 1996, is testing an oral pill called Exebryl-1 in clinical trials for mild to moderate Alzheimer’s disease, and has another drug in animal testing for Parkinson’s disease, according to its website. Chairman Alan Snow couldn’t be reached for comment.
San Francisco · 6/3/13
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
Pingback: Today’s Financings, Deals and Venture Updates… | IguanaBio - A Daily Biotech and Pharma Tabloid - Gossip, News, Research, Humor and Updates on the Latest Events in Biotech and Pharma - Unique, Insightful, Truthful, Sometimes Sneaky